Stay ahead with our blog, your go-to source for the latest in healthcare
technology, policy, and research.
Real-world data (RWD) from electronic health records (EHRs) is increasingly recognized as a powerful asset for oncology research. It enables stakeholders across industry and academia to evaluate treatment patterns, assess comparative effectiveness, identify safety signals, and inform regulatory and market access strategies. RWD has supported external control arms, augmented clinical trial enrollment, and
At COTA, we believe the future of healthcare is shaped not only by innovation and data but by people. Each summer, we’re excited to welcome a group of bright, driven interns who bring fresh perspectives, unique talents, and a shared passion for meaningful impact. This year is no exception. Our 2025 intern class includes students […]
…
Four Ways Pharmaceutical Companies Are De-Risking R&D with Real-World Data Pharmaceutical research and development is inherently complex and high-risk. Sponsors must ensure that investigational products demonstrate both strong therapeutic efficacy and an acceptable safety profile. At the same time, they must manage escalating costs, lengthy timelines, and increasing expectations from regulators, payers, and patients. Despite […]
…
Cancer affects everyone, including adolescents and young adults who are at increasing risk of developing certain types of disease. It’s a particularly challenging time of life to receive a cancer diagnosis. Many cancers in younger patients can be aggressive, and treatment can be complicated, expensive, painful, and isolating for young people who should be focused […]
…
3 key takeaways from ASCO 2025: Staying nimble in a changing environment The annual meeting of the American Society of Clinical Oncology (ASCO) is a chance for oncology professionals, patient advocates, data experts, and industry representatives to come together and share the latest research in cancer care. This year, thousands of attendees descended on Chicago […]
…
How real-world data can tell the story of breast, ovarian and uterine cancers at a pivotal moment in women’s health Nearly 4 million women worldwide are diagnosed with breast or gynecological cancers each year. Yet too many factors around these diseases are still poorly understood, including why there are so many disparities and variances in […]
…
Nearly 4 million women worldwide are diagnosed with breast or gynecological cancers each year. Yet too many factors around these diseases are still poorly understood, including why there are so many disparities and variances in treatment and outcomes. Clinical trials have been helpful in illuminating some of these issues. And early approaches to leveraging real-world […]
…
